Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ranbaxy Files For Phase I Trial On First Compound From GSK Deal

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - A year after identifying a potential compound targeted at respiratory inflammation for joint development with GSK Pharma, India's largest drug maker, Ranbaxy has submitted an application to the Drug Controller General of India to initiate Phase I trials

You may also be interested in...

Two Months On, U.S. DOJ Withdraws Motion Against Ranbaxy

MUMBAI - Two months after filing a motion to enforce subpoenas against Indian drug maker Ranbaxy, the U.S. Department of Justice has withdrawn from taking further action. "The DOJ expressed its satisfaction with the documents submitted by Ranbaxy and Parexel Consulting," a source familiar with the issue informed PharmAsia News.

A Tale Of Two Giants; Tracking India And China’s Rise In The Pharmaceutical Market

SHANGHAI - The nature of business relationships between multinational pharma companies and Indian and Chinese firms varies significantly, according to a recent study released by the Ewing Marion Kauffman Foundation

Ranbaxy/GSK Partnership Yields First Drug Candidate

Ranbaxy and GlaxoSmithKline have identified the first clinical candidate to be developed under their discovery alliance, the two firms announced April 2




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts